Portal de Periódicos da CAPES

Protective antibodies and T cell responses to Omicron variant after the booster dose of BNT162b2 vaccine

2022; Elsevier BV; Volume: 3; Issue: 8 Linguagem: Inglês

10.1016/j.xcrm.2022.100716

2666-3791

Paul Naaber, Liina Tserel, Kadri Kangro, Marite Punapart, Epp Sepp, Virge Jürjenson, Jaanika Kärner, Liis Haljasmägi, Uku Haljasorg, Marilin Kuusk, Eve Sankovski, Anu Planken, Mart Ustav, Eva Žusinaite, Joachim M. Gerhold, Kai Kisand, Pärt Peterson,

Bacillus and Francisella bacterial research

The high number of mutations in the Omicron variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes its immune escape. We report a longitudinal analysis of 111 vaccinated individuals for their antibody levels up to 6 months after the third dose of the BNT162b2 vaccine. After the third dose, the antibody levels decline but less than after the second dose. The booster dose remarkably increases the serum ability to block wild-type or Omicron variant spike protein's receptor-binding domain (RBD) interaction with the angiotensin-converting enzyme 2 (ACE2) receptor, and these protective antibodies persist 3 months later. Three months after the booster dose, memory CD4+ and CD8+ T cells to the wild-type and Omicron variant are detectable in the majority of vaccinated individuals. Our data show that the third dose restores the high levels of blocking antibodies and enhances T cell responses to Omicron.